Breyanzi has shown significant efficacy and durable responses in patients with marginal zone lymphoma. Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 ...

CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...

Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma in Uganda The cohort included 103 patients (63.1% female, 36.9% ...

Credit: Bristol Myers Squibb. The approval was based on data from the MZL cohort of the open-label, single-arm, phase 2 TRANSCEND FL trial. Breyanzi is prepared from the patient’s T cells, which are ...

PLYMOUTH MEETING, PA [September 12, 2022] — The National Comprehensive Cancer Network ® (NCCN ®) has published new NCCN Guidelines for Patients ®: Marginal Zone Lymphoma. A cancer of the lymphatic ...

This week, the FDA granted priority review to a supplemental new drug application (sNDA) for zanubrutinib (Brukinska) as a treatment option for adults with marginal zone lymphoma who have previously ...

Breyanzi achieved a 95.5% response rate in relapsed or refractory marginal zone lymphoma, with 62.1% complete responses and 88.6% ongoing at 24 months. The therapy maintained a consistent safety ...

A Prescription Drug User Fee Act target date of December 5, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...

This is the third approval for zanubrutinib, which is sold as Brukinsa by BeiGene. Zanubrutinib, a second-generation selective inhibitor of Bruton's tyrosine kinase (BTK), received accelerated ...

Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma in Uganda This retrospective cohort study included patients ...